Chronic (-)-Δ9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats

European Journal of Pharmacology

Volumn 365, Issue 2-3, 1999, Pages 133-142

  Gorriti, Miguel Angel ^a   Rodríguez De Fonseca, Fernando ^b   Navarro, Miguel ^b   Palomo, Tomás ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b NONE

Author keywords

Amphetamine; Behavior; Cannabinoid; Dopamine; Locomotion; Psychosis; Sensitization

Indexed keywords

AMPHETAMINE; CANNABINOID RECEPTOR; TETRAHYDROCANNABINOL; PSYCHOTROPIC AGENT;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; EXPLORATORY BEHAVIOR; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; SENSITIZATION; STEREOTYPY; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECT; DRUG POTENTIATION; LOCOMOTION; TIME; WISTAR RAT;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; LOCOMOTION; MALE; PSYCHOTROPIC DRUGS; RATS; RATS, WISTAR; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 0032587994     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00851-6     Document Type: Article

References (55)

1. Abood M.E., Martin B.R. Neurobiology of marijuana abuse. Trends Neurosci. 13:1992;201-206.
2. Andreasson S., Allebeck P., Engström A., Rydberg V. Cannabis and schizophrenia: a longitudinal study of swedish conscripts. Lancet. ii:1987;1483-1486.
3. Ashcroft G.W., Blackwood G.W., Besson J.A.O., Palomo T.A., Waring H.L. Positive and negative schizophrenic symptoms and the role of dopamine. Br. J. Psychiatry. 138:1981;268-269.
4. Bowers M.B., Hoffman F.J. Regional brain homovanilic acid following delta-9-tetrahydrocannabinoland cocaine. Brain Res. 366:1986;405-407.
5. Cadogan A.K., Alexander S.P.H., Boyd E.A., Kendall D.A. Influence of cannabinoids on electrically evoked release and cAMP generation in the rat striatum. J. Neurochem. 69:1997;1131-1237.
6. Chen J., Paredes W., Li J., Smith D., Lowinson J., Gardner E.L. Delta-9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology. 102:1990;156-162.
7. Coryell W., Tsunag D. Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis: recovery during an 8-year follow up. Am. J. Psychiatry. 149:1992;1033-1039.
8. Crow T.J. Positive and negative schizophrenia symptoms and the role of dopamine. Br. J. Psychiatry. 137:1980;383-386.
9. Darracq L., Blanc G., Glowinski J., Tassin J.P. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. J. Neurosci. 18:1998;2729-2739.
10. Devane W.A., Dysarz III F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
11. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson R.G., Griffin G., Gibson D., Mandelbaum L.A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
12. Emrich H.M., Leweke M., Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol. Biochem. Behav. 56:1997;803-807.
13. Gardner E.L., Lowinson J.H. Marijuana's interaction with brain reward systems: update 1991. Pharmacol. Biochem. Behav. 40:1991;571-580.
14. Glass M., Brotchie J.M., Meneuf Y.P. Modulation of neurotransmission by cannabinoids in the basal ganglia. Eur. J. Neurosci. 9:1997;199-203.
15. Hattendorf C., Hattendorf C., Coper H., Fernandes M. Interaction of delta(9)-tetrahydrocannabinol and D-amphetamine. Psychopharmacology. 54:1977;177-182.
16. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. PNAS (USA). 87:1990;1932-1936.
17. Herkenham M., Lynn A.B., de Costa B.R., Richfield E.K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547:1991;267-274.
18. Howlet A.C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35:1995;607-634.
19. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug and stress-induced sensitization of motor activity. Brain Res. Rev. 16:1991;223-224.
20. Knudsen P., Vilmar P. Cannabis and neuroleptics agents in schizophrenia. Acta Physciatr. Scand. 69:1984;162-164.
21. Koob G.F., Le Moal F. Drug abuse: hedonic homeostatic dysregulation. Science. 278:1997;52-58.
22. 1-tetrahydrocannabinol in rats. Eur. J. Pharmacol. 14:1971;89-92.
23. Maccari S., Piazza P.V., Deminiere J.M., Lemaire V., Mormede P., Simon H., Angelucci L., Le Moal M. Life events-induced decrease of corticosteroid type-I receptors is associated with reduced corticosterone feedback and enhanced vulnerability to amphetamine self-administration. Brain Res. 547:1991;7-12.
24. Mailleux P., Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 48:1992;655-668.
25. Mailleux P., Vanderhaeghen J.J. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J. Neurochem. 61:1993;1705-1712.
26. Makanjoula R.O.A., Hill G., Dow R.C., Campbell G., Ashcroft G.W. The effects of psychotropic drugs on exploratory and stereotyped behaviour of rats studied in a hole-board. Psychopharmacology. 55:1977;67-74.
27. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
28. Moss D.E., Mcmaster S.B., Rogers J. Tetrahydrocannabinol potentiates reserpine-induced hipokinesia. Pharmacol. Biochem. Behav. 15:1981;779-783.
29. Moss D.E., Koob G.F., Mcmaster S.B., Janowsky D.S. Comparative effects of tetrahydrocannabinol on psychostimulant-induced behaviors. Pharmacol. Biochem. Behav. 21:1984;641-644.
30. 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. Behav. Brain. Res. 5:1993;37-46.
31. Navarro M., Fernández-Ruiz J.J., de Miguel R., Hernández M.L., Cebeira M., Ramos J.A. Motor disturbances induced by an acute dose of delta-9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations. Pharmacol. Biochem. Behav. 45:1993;291-298.
32. Navarro M., Hernández E., Muñoz R.M., Del Arco I., Villanúa M.A., Carrera M.R., Rodriguez de Fonseca F. Acute administration of CB1 receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport. 8:1997;491-496.
33. Ng Cheong Ton J.M., Gerhardt S.A., Freidman M., Etgen A., Rose G.M., Sharlegg N.S., Gardner E.L. The effect of delta-9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study. Brain Res. 451:1988;59-68.
34. Nuñez-Dominguez, L.A., 1997. Gurpegui-Fernández de Legaria, M., 1997. Cannabis psychosis: a five year follow-up study. International Meeting on Interactive Monoaminergic Brain Disorders. October 8-12, 1997, P3.5, p. 76.
35. Palomo, T., 1994. A clinician's view of animal research in schizophrenia studies. In: Palomo, T., Archer, T., Beninger, R. (Eds.), Strategies for Studying Brain Disorders, Vol. 2. Farrand Press, London, pp. 95-142.
36. Piazza P.V., Le Moal M. Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids and dopaminergics neurons. Annu. Rev. Pharmacol. Toxicol. 36:1996;359-378.
37. Piazza P.V., Deminière J.M., Le Moal M., Simon H. Factors that predict individual vulnerability to amphetamine self-administration. Science. 245:1989;1511-1513.
38. Piazza P.V., Barrot M., Rougé-Pont F., Marinelli M., Maccari S., Abrous D.N., Simon H., Le Moal M. Suppression of glucocorticoid secretion and antipsychotic drugs have similar effect on the mesolimbic dopaminergic transmission. Proc. Natl. Acad. Sci. U.S.A. 93:1996;15445-15450.
39. Pryor G.T., Larsen F.F., Husain S., Braude M.C. Interactions of delta-9-tetrahydrocannabinol with D-amphetamine, cocaine and nicotine in rats. Pharmacol. Biochem. Behav. 8:1978;295-318.
40. Richter R.M., Merlo E., Koob G.F., Weiss F. Sensitization of cocaine-stimulated increase in extracellular levels of corticotropin-releasing factor from the rat amygdala after repeated administration as determined by intracranial microdialysis. Neurosci. Lett. 189:1995;169-172.
41. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of psychosis. Brain. Res. Rev. 11:1986;157-198.
42. Rodríguez de Fonseca F.A., Fernández-Ruiz J.J., Eldridge J.C., Steger R.W., Bartke A., Murphy L.L. Effects of the exposure to delta-9-tetrahydrocannabinol on the adrenal medullary function: evidence of an acute effect and development of tolerance in chronic treatments. Pharmacol. Biochem. Behav. 40:1991;593-598.
43. Rodriguez de Fonseca F., Fernández Ruiz J.J., Murphy L.L., Cebeira M., Steger R.W., Bartke A., Ramos J.A. Acute effects of delta-9-tetrahydrocannabinol on dopaminergic activity in several rat brain areas. Pharmacol. Biochem. Behav. 42:1992;269-275.
44. Rodriguez de Fonseca F., Gorriti M.A., Fernández-Ruiz J.J., Palomo T., Ramos J.A. Down regulation of rat brain cannabinoid binding sites after chronic delta-9-tetrahydrocannabinol treatment. Pharmacol. Biochem. Behav. 47:1994;33-40.
45. 8-tetrahydrocannabinol-dimethylheptyl-induced catalepsy in male rats. Neuroreport. 5:1994;761-765.
46. Rodríguez de Fonseca F., Villanúa M.A., Muñoz R.M., San-Martin-Clarke O., Navarro M. Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats. Neuroendocrinology. 61:1995;714-721.
47. Rodríguez de Fonseca F., Carrera M.R.A., Navarro M., Koob G.F., Weis F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 276:1997;2050-2054.
48. Romero J., Garcia-Palomero E., Fernández-Ruiz J.J., Ramos J.A. Involvement of GABA-B receptors in the motor inhibition produced by agonist of brain cannabinoid receptors. Behav. Pharmacol. 7:1995;299-302.
49. Romero J., Garcia-Palomero E., Lin S.Y., Ramos J.A., Makriyannis A., Fernández-Ruiz J.J. Extrapiramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand. Life Sci. 58:1996;1249-1275.
50. Rubino T., Patrini G., Parenti M., Massi P., Parolaro D. Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Mol. Brain Res. 44:1997;191-197.
51. Snyder S.H. Amphetamine psychosis: a model schizophrenia mediated by catecholamines. Am. J. Psychiatry. 130:1973;61-67.
52. Sorg B.A., Kalivas P.W. Behavioral sensitization to stress and psychostimulants: role of dopamine and excitatory amino acids in the mesocorticolimbic system. Sem. Neurosci. 5:1993;343-350.
53. Sulzer D., Maidment N.T., Rayport S. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J. Neurochem. 60:1993;527-535.
54. Weidenfeld J., Feldman S., Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology. 59:1993;110-112.
55. Wolf M.E., White F.J., Nassar R., Brooderson R.J., Khansa M.R. Differential development of autoreceptor subsensitivity and enhanced dopamine release during amphetamine sensitization. J. Pharmacol. Exp. Ther. 264:1993;249-255.